NASDAQ:BCRX

Biocryst Pharmaceuticals Stock Predictions

Healthcare > Biotechnology

Buy BCRX

*Your capital is at risk

$8.25

-0.0900 (-1.08%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

BCRX Prediction Chart

BCRX Predictions History

Latest community submissions for BCRX.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
Issou	Nov 21, 2019	$2.50 +11.61%	$2.24	X	88.39%	1
NameNotImportant Pro	May 6, 2019	$7.81 -3.70%	$8.11	X	96.30%	0
NameNotImportant Pro	Apr 29, 2019	$7.52 +0.13%	$7.51	X	99.87%	5
Joey.floyd.96225	Jan 18, 2019	$10.00 +6.50%	$9.39	X	93.50%	0
Christi.SC.Closeouts.89991	Oct 16, 2018	$7.22 +0.28%	$7.20	X	99.70%	4
JS Pro	Oct 16, 2018	$6.97 -3.19%	$7.20	X	96.80%	0
JS Pro	Apr 13, 2017	$6.70 -0.74%	$6.75	X	99.30%	3
JuanC Villegas Pro	Apr 13, 2017	$7.27 +7.70%	$6.75	X	92.30%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for BCRX with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT BIOCRYST PHARMACEUTICALS

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by